Skip to Content

Axsome Therapeutics Inc AXSM Stock Quote

| Rating as of

Morningstar‘s Stock Analysis AXSM

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics AXSM

Company Profile AXSM

Business Description

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Contact
22 Cortlandt Street, 16th Floor
New York, NY, 10007
T +1 212 332-3241
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 198